FcγRIIIa gene polymorphism is associated with increased susceptibility to RA [47] and influences treatment outcomes in patients with RA or psoriatic arthritis treated with TNF-α blocking drugs and rituximab [48, 49]. This evidence concerns the gene TNF and rheumatoid arthritis.